The text starts here.

News Release

FOR IMMEDIATE RELEASE
January 30, 2015

Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2015

Listed Company Name: Eisai Co., Ltd.
Representative: Haruo Naito
Representative Corporate
Officer and CEO
Securities Code: 4523
Stock Exchange Listings: First Section of the Tokyo
Stock Exchange
Inquiries: Sayoko Sasaki
Vice President, Corporate Affairs
Phone +81-3-3817-5120

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 2015 (April 1, 2014 to March 31, 2015) previously announced on May 13, 2014, as follows:

1.  Revised full-year consolidated financial results forecasts for the fiscal year ending March 31, 2015 (April 1, 2014 to March 31, 2015)
(Unit: Millions of yen, unless otherwise noted.)
  Revenue Operating
profit
Profit before
income taxes
Profit for
the period
Basic
earnings
per share
Previously announced forecast (A)
(May 13, 2014)
566,000 53,000 49,500 35,000 122.37 yen
Currently revised forecast (B) 555,000 30,000 27,000 35,000 121.97 yen
Change in amount (B - A) -11,000 -23,000 -22,500 -   
Percentage of change (%) -1.9% -43.4% -45.5% -   
(Reference) Business results for the fiscal year ended March 31, 2014 599,490 66,398 62,298 38,501 134.13 yen

2.  Reason for revision of the consolidated financial results forecasts
  Revenue is forecasted to be ¥555,000 million (down ¥11,000 million from the previous forecast) due to factors such as greater than expected generic erosion within Japan and the slow growth of new products in the United States. Revenue for major products is forecasted to be ¥57,000 million for Pariet®/AcipHex® (up ¥4,000 million from the previous forecast), ¥68,500 million for Aricept® (down ¥7,000 million from the previous forecast), ¥36,500 million for Halaven® (down ¥2,500 million from the previous forecast) and ¥5,000 million for Fycompa® (down ¥4,500 million from the previous forecast).

  Operating profit is forecasted to be ¥30,000 million (down ¥23,000 million from the previous forecast) due to factors such a decline in gross profit, proactive expenditure aimed at returning to a growth trajectory from fiscal 2015 onward as well as the influence of exchange rates.

  Regarding profit for the period, a decrease in tax expenses is expected due to the repayment of paid-in capital of a U.S. subsidiary of the Group. On the other hand, an increase in tax expenses is also expected due to a decrease in deferred tax assets brought about by changes in the corporate tax rate. As a result, a net reduction in tax expenses of approximately ¥20,000 million is being expected and therefore profit for the period is forecasted to be ¥35,000 million, unchanged from previous forecasts. Furthermore, the forecast for the total dividend for the year remains unchanged at ¥150 per share (same amount as the previous fiscal year).

***